US EditionPublished • loading... • Updated
Ozempic maker Novo Nordisk lowers growth outlook for its weight loss drugs as pricing pressures mount
- This year, Novo Nordisk narrowed its guidance after lowering growth expectations for GLP-1 treatments, reporting a quarter net profit of 20 billion Danish kroner.
- Rising competition and U.S. pricing pressures prompted the company to lower growth expectations, citing prescription trends and transformation with DKK 95.9 billion restructuring costs affecting outlooks.
- Robust year-to-date sales coexist with softer near-term growth expectations for GLP-1 medicines, with Diabetes & Obesity sales at DKK 215.7 billion driven by 37% growth in Obesity care to DKK 59.9 billion.
- Investors have punished the stock, with shares falling more than 50% this year, while the Board called an EGM to elect new board members accessible via the investor link.
- Meanwhile, the company is adding assets—agreeing to buy Akero and cagrilintide, and secured Wegovy MASH approval, while Pfizer filed a lawsuit alleging anticompetitive conduct.
Insights by Ground AI
Podcasts & Opinions
21 Articles
21 Articles
The once most valuable European company feels the tough competition. Weight loss products are now available to other companies - albeit not always legally. Novo Nordisk has long been fighting against with a austerity program, but has to adjust the annual targets downwards again.
Danish diet giant Novo Nordisk is once again failing to live up to expectations.
·Stockholm, Sweden
Read Full ArticleCoverage Details
Total News Sources21
Leaning Left3Leaning Right2Center9Last UpdatedBias Distribution64% Center
Bias Distribution
- 64% of the sources are Center
64% Center
L 22%
C 64%
14%
Factuality
To view factuality data please Upgrade to Premium
